Researchers from the University of Notre Dame have announced a breakthrough approach to allergy treatment that inhibits food allergies, drug allergies and asthmatic reactions without suppressing a sufferer’s entire immunological system.
The therapy centers on a special molecule the researchers designed, a heterobivalent ligand (HBL), which when introduced into a person’s bloodstream can, in essence, out-compete allergens like egg or peanut proteins in their race to attach to mast cells, a type of white blood cell that is the source of type-I hypersensitivity (that is, allergy).
“Unlike most current treatments, this approach prevents allergic reactions from occurring in the first place,” says Basar Bilgicer, assistant professor of chemical and biomolecular engineering and chemistry and biochemistry and principal investigator in Notre Dame’s Advanced Diagnostics & Therapeutics initiative
Chemistry and Biology Journal – Design of a Heterobivalent Ligand to Inhibit IgE Clustering on Mast Cells
Mast cells are part of the human body’s defense against parasites (such as tapeworms), and when working normally they are attracted to, attach to, and annihilate these pathogens. But type-I hypersensitivity occurs when the cells react to non-threatening substances. More common allergies are due to ambient stimulants, and an allergic response may range from a mild itch to life-threatening anaphylactic shock.
Tanyel Kiziltepe, a research professor in Advanced Diagnostics & Therapeutics, adds that “anaphylaxis can be caused by certain food allergens, insect stings, antibiotics and some medicines, and we believe HBL has a very high potential to be developed as a preventative medication.”
While many medicines treat allergies by weakening a person’s entire immune system, this approach only disrupts the process whereby white blood cells bond with allergens in the first place.
“It also does not leave patients open to an increased risk for infections or the development of cancers,” explains Bilgicer. “HBLs may be most useful in situations where it’s not possible to speak to or gauge someone’s sensitivity.”
“For example, in an emergency, on a battlefield, or in a remote location, doctors may not be able to ask a patient about an allergy before administering penicillin. An engineered HBL could be given along with the medicine and perhaps prevent a deadly reaction from occurring.”
If you liked this article, please give it a quick review on ycombinator or StumbleUpon. Thanks
Brian Wang is a Futurist Thought Leader and a popular Science blogger with 1 million readers per month. His blog Nextbigfuture.com is ranked #1 Science News Blog. It covers many disruptive technology and trends including Space, Robotics, Artificial Intelligence, Medicine, Anti-aging Biotechnology, and Nanotechnology.
Known for identifying cutting edge technologies, he is currently a Co-Founder of a startup and fundraiser for high potential early-stage companies. He is the Head of Research for Allocations for deep technology investments and an Angel Investor at Space Angels.
A frequent speaker at corporations, he has been a TEDx speaker, a Singularity University speaker and guest at numerous interviews for radio and podcasts. He is open to public speaking and advising engagements.